ConductScience.org, home

Comparison · NCT02722278-7bee4a5d

Oral TU Cosyntropin Substudy Subjects vs Axiron Cosyntropin Substudy Subjects: Number of Participants With Post-stimulation Cortisol Level of >18 ug/dL at Visit 8

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Oral TU Cosyntropin Substudy Subjects vs Axiron Cosyntropin Substudy Subjects: Number of Participants With Post-stimulation Cortisol Level of >18 ug/dL at Visit 8. Trial comparisons, record NCT02722278-7bee4a5d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02722278-7bee4a5d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7920.5950.908wilson
Risk in group 210.6761wilson
Risk difference, group 1 minus group 2-0.208-0.4050.136newcombe hybrid score
Risk ratio, group 1 over group 20.7920.6450.972log
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one fewer participant with the outcome on Oral TU Cosyntropin Substudy Subjects than on Axiron Cosyntropin Substudy Subjects4.8from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Oral TU Cosyntropin Substudy SubjectsSubjects receiving Oral TU participating in cosyntropin substudy1924OG000
Group 2Axiron Cosyntropin Substudy Subjects88OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Number of Participants With Post-stimulation Cortisol Level of >18 ug/dL at Visit 8
Description
Compare the Oral TU-treated subjects and the Topical Axiron®-treated subjects with respect to number of subjects in the cosyntropin stimulation test substudy with a normal maximum post-stimulation (cosyntropin stimulation) cortisol level at Visit 8.
Time frame
Approximately 4.5 months
Population

Source ClinicalTrials.gov

Trial

Title
A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
NCT number
NCT02722278
Phases
PHASE3
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate, Axiron Testosterone Topical Solution
Lead sponsor
Clarus Therapeutics, Inc.
Results first posted
2018-02-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02722278-7bee4a5d